William Blair Has Pessimistic Outlook of USPH Q1 Earnings

U.S. Physical Therapy, Inc. (NYSE:USPH) – Research analysts at William Blair decreased their Q1 2025 earnings estimates for U.S. Physical Therapy in a note issued to investors on Tuesday, March 11th. William Blair analyst J. Haase now forecasts that the company will post earnings of $0.48 per share for the quarter, down from their prior estimate of $0.56. William Blair has a “Market Perform” rating on the stock. The consensus estimate for U.S. Physical Therapy’s current full-year earnings is $2.67 per share. William Blair also issued estimates for U.S. Physical Therapy’s Q2 2025 earnings at $0.71 EPS, Q3 2025 earnings at $0.77 EPS, Q4 2025 earnings at $0.76 EPS, FY2025 earnings at $2.73 EPS and FY2026 earnings at $3.05 EPS.

U.S. Physical Therapy (NYSE:USPH) last announced its earnings results on Wednesday, February 26th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04). The firm had revenue of $180.45 million during the quarter, compared to the consensus estimate of $173.10 million. U.S. Physical Therapy had a return on equity of 8.11% and a net margin of 3.54%.

Several other equities analysts have also commented on USPH. JPMorgan Chase & Co. increased their price objective on shares of U.S. Physical Therapy from $117.00 to $120.00 and gave the company an “overweight” rating in a research report on Tuesday, December 3rd. Bank of America raised shares of U.S. Physical Therapy from a “neutral” rating to a “buy” rating and increased their price objective for the company from $100.00 to $115.00 in a research report on Monday, December 16th. Citizens Jmp raised shares of U.S. Physical Therapy to a “strong-buy” rating in a research report on Monday, December 16th. StockNews.com lowered shares of U.S. Physical Therapy from a “hold” rating to a “sell” rating in a research report on Friday, February 28th. Finally, JMP Securities started coverage on shares of U.S. Physical Therapy in a research report on Monday, December 16th. They issued an “outperform” rating and a $113.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $111.50.

U.S. Physical Therapy Stock Performance

Shares of U.S. Physical Therapy stock opened at $76.68 on Thursday. The company has a market capitalization of $1.16 billion, a PE ratio of 81.57, a P/E/G ratio of 3.54 and a beta of 1.51. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.78 and a current ratio of 1.78. The company has a 50-day simple moving average of $86.40 and a two-hundred day simple moving average of $87.36. U.S. Physical Therapy has a one year low of $76.18 and a one year high of $113.63.

U.S. Physical Therapy Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 11th. Investors of record on Friday, March 14th will be issued a $0.45 dividend. This represents a $1.80 annualized dividend and a yield of 2.35%. The ex-dividend date is Friday, March 14th. This is an increase from U.S. Physical Therapy’s previous quarterly dividend of $0.44. U.S. Physical Therapy’s dividend payout ratio is 97.83%.

Insider Buying and Selling

In other news, COO Graham D. Reeve sold 1,730 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $82.11, for a total transaction of $142,050.30. Following the sale, the chief operating officer now owns 7,168 shares of the company’s stock, valued at $588,564.48. This trade represents a 19.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On U.S. Physical Therapy

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its stake in shares of U.S. Physical Therapy by 283.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,842 shares of the company’s stock worth $1,425,000 after purchasing an additional 12,445 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of U.S. Physical Therapy by 57.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,631 shares of the company’s stock worth $223,000 after purchasing an additional 956 shares during the period. State Street Corp grew its stake in shares of U.S. Physical Therapy by 17.5% during the 3rd quarter. State Street Corp now owns 667,868 shares of the company’s stock worth $56,522,000 after purchasing an additional 99,244 shares during the period. Stifel Financial Corp grew its stake in shares of U.S. Physical Therapy by 12.1% during the 3rd quarter. Stifel Financial Corp now owns 57,166 shares of the company’s stock worth $4,838,000 after purchasing an additional 6,154 shares during the period. Finally, Quest Partners LLC grew its stake in U.S. Physical Therapy by 2,368.2% in the 3rd quarter. Quest Partners LLC now owns 8,614 shares of the company’s stock valued at $729,000 after acquiring an additional 8,265 shares during the period.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.